34 results
6-K
EX-99.3
LSB
LakeShore Biopharma Co., Ltd
7 May 24
Report of Foreign Private Issuer
4:30pm
and safety evaluations. Dr. Xu’s career in toxicological research began at Duke University, where he completed his dissertation before conducting … and regulation demonstrate his commitment to advancing medical science and public health safety globally.
A-3
Dr. Xu earned his Bachelor of Medicine from
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
18 Apr 24
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
8:15am
to conduct the clinical trial to the highest safety and ethical standards, and we are eager to take the next step towards delivering these much … medical need. This trial will employ a double-blind, randomized, placebo-controlled, dose-escalation approach, and aims to evaluate the safety
6-K
EX-99.1
LSB
LakeShore Biopharma Co., Ltd
9 Apr 24
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
8:20am
-blind, multicenter trial which includes 4,500 participants from the Philippines and Pakistan. It is designed to assess the immunogenicity, safety, and lot … to safety, with the safety profile of the PIKA Rabies Vaccine remaining highly tolerable.
Dr. Zenaida Mojares, Chief Medical Officer of YS Biopharma
POS AM
ts3pj3u4vqu q6xky6x
23 Jan 24
Prospectus update (post-effective amendment)
4:18pm
6-K
EX-99.1
ttpgpux
22 Jan 24
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
5:10pm
6-K
EX-99.1
pdh1tx0rzz s1byc
14 Nov 23
Report of Foreign Private Issuer
12:00am
424B3
slv5rju26u
31 Oct 23
Prospectus supplement
8:46am
6-K
EX-99.1
trjhxgeuh
31 Oct 23
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
8:45am
424B3
55x91hw 4gw76u
26 Sep 23
Prospectus supplement
9:13am
6-K
EX-99.1
yg366j ug7wxyaz0
26 Sep 23
YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
9:10am
424B3
xqk9617ogou1t m8
25 Sep 23
Prospectus supplement
6:07am
6-K
EX-99.1
6o9u3n85vfccrj
16 Aug 23
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
8:00am
424B3
2d9fy8
15 Aug 23
Prospectus supplement
8:00am
POS AM
vqk3o0l6jcn01f
8 Aug 23
Prospectus update (post-effective amendment)
4:06pm
20-F
cty68b11zvs9 xy
26 Jul 23
Annual report (foreign)
4:02pm
424B3
37yypmhtr22znz jd
5 Jun 23
Prospectus supplement
4:03pm
6-K
EX-99.1
xk02qftm
1 Jun 23
YS Biopharma’s PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
9:00am
6-K
EX-99.1
p1r62or1
16 May 23
YS Biopharma’s PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
10:38am